In 2024, the World Health Organization (WHO) designated antimicrobial-resistant Neisseria gonorrhoeae as a high-priority pathogen.1 Yet only 3% of antimicrobial drugs currently in development target this organism.2 Resistance has emerged against all previously used antibiotics, and strains showing reduced susceptibility to the few remaining options are increasing, making untreatable gonorrhoea an imminent global threat.3,4 Drug repurposing offers a promising strategy for antimicrobial discovery. We screened over 1,000 non-antibacterial compounds - spanning all stages of the drug development pipeline - against 16 species from the WHO Global Priority Pathogen List, with a particular focus on N. gonorrhoeae. Several candidates are being advanced as potential novel therapies for drug-resistant gonorrhoea. Our top compounds have been tested against more than 20 N. gonorrhoeae strains with diverse resistance profiles, yielding encouraging results. Current work aims to determine their antibacterial mechanisms, their efficacy in eradicating infection within mammalian cells, and assess the likelihood of resistance development.